MX2009001875A - Compuestos de aza-benzotiofenilo y metodos de uso de los mismos. - Google Patents

Compuestos de aza-benzotiofenilo y metodos de uso de los mismos.

Info

Publication number
MX2009001875A
MX2009001875A MX2009001875A MX2009001875A MX2009001875A MX 2009001875 A MX2009001875 A MX 2009001875A MX 2009001875 A MX2009001875 A MX 2009001875A MX 2009001875 A MX2009001875 A MX 2009001875A MX 2009001875 A MX2009001875 A MX 2009001875A
Authority
MX
Mexico
Prior art keywords
alkyl
cr19r20
nhc
cr14r15
formula
Prior art date
Application number
MX2009001875A
Other languages
English (en)
Spanish (es)
Inventor
Stephen Price
Hazel Joan Dyke
Karen Williams
Pascal Pierre Savy
John Gary Montana
Mark S Stanley
Liang Bao
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38800915&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009001875(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2009001875A publication Critical patent/MX2009001875A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4743—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX2009001875A 2006-08-21 2007-08-20 Compuestos de aza-benzotiofenilo y metodos de uso de los mismos. MX2009001875A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US83916306P 2006-08-21 2006-08-21
US87160006P 2006-12-22 2006-12-22
US91762407P 2007-05-11 2007-05-11
PCT/US2007/076340 WO2008024724A1 (en) 2006-08-21 2007-08-20 Aza-benzothiophenyl compounds and methods of use

Publications (1)

Publication Number Publication Date
MX2009001875A true MX2009001875A (es) 2009-03-02

Family

ID=38800915

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009001875A MX2009001875A (es) 2006-08-21 2007-08-20 Compuestos de aza-benzotiofenilo y metodos de uso de los mismos.

Country Status (16)

Country Link
US (1) US7893085B2 (cg-RX-API-DMAC10.html)
EP (1) EP2069359B1 (cg-RX-API-DMAC10.html)
JP (1) JP5349306B2 (cg-RX-API-DMAC10.html)
KR (1) KR101475088B1 (cg-RX-API-DMAC10.html)
AR (1) AR062469A1 (cg-RX-API-DMAC10.html)
AU (1) AU2007286807B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0714629A2 (cg-RX-API-DMAC10.html)
CA (1) CA2660963A1 (cg-RX-API-DMAC10.html)
CL (1) CL2007002431A1 (cg-RX-API-DMAC10.html)
ES (1) ES2528797T3 (cg-RX-API-DMAC10.html)
IL (1) IL197060A (cg-RX-API-DMAC10.html)
MX (1) MX2009001875A (cg-RX-API-DMAC10.html)
NO (1) NO20091198L (cg-RX-API-DMAC10.html)
PE (2) PE20120049A1 (cg-RX-API-DMAC10.html)
TW (1) TWI426078B (cg-RX-API-DMAC10.html)
WO (1) WO2008024724A1 (cg-RX-API-DMAC10.html)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE531720T1 (de) * 2006-08-21 2011-11-15 Genentech Inc Aza-benzofuranylverbindungen und anwendungsverfahren dafür
EP2370568B1 (en) 2008-12-10 2017-07-19 Dana-Farber Cancer Institute, Inc. Mek mutations conferring resistance to mek inhibitors
RU2571930C2 (ru) 2010-02-25 2015-12-27 Дана-Фарбер Кэнсер Инститьют, Инк. Мутации braf, обеспечивающие резистентность к ингибиторам braf
US20130059851A1 (en) 2010-03-09 2013-03-07 Dana-Farber Cancer Institute, Inc. Methods of Diagnosing and Treating Cancer in Patients Having or Developing Resistance to a First Cancer Therapy
EP2844655A1 (en) 2012-05-02 2015-03-11 Lupin Limited Substituted pyridine compounds as crac modulators
WO2013169858A1 (en) 2012-05-08 2013-11-14 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
CA2890238A1 (en) 2012-11-02 2014-05-08 Merck Patent Gmbh Method of reducing adverse effects in a cancer patient undergoing treatment with a mek inhibitor
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
US20170114323A1 (en) 2014-06-19 2017-04-27 Whitehead Institute For Biomedical Research Uses of kinase inhibitors for inducing and maintaining pluripotency
GB201508026D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Capsid
WO2017112777A1 (en) * 2015-12-22 2017-06-29 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
EP3443114A1 (en) 2016-04-15 2019-02-20 H. Hoffnabb-La Roche Ag Diagnostic and therapeutic methods for cancer
KR102659322B1 (ko) * 2017-05-19 2024-04-22 엔플렉션 테라퓨틱스, 인코포레이티드 피부병 치료를 위한 융합된 헤테로방향족-아닐린 화합물
CN111065393B (zh) 2017-05-19 2023-08-18 恩福莱克逊治疗有限公司 用于治疗皮肤疾病的吡咯并吡啶-苯胺类化合物
KR102736865B1 (ko) 2017-06-21 2024-12-03 샤이 테라퓨틱스 엘엘씨 암, 염증성 질환, 신경발달질환 및 섬유증 질환의 치료를 위하여 Ras 수퍼패밀리와 상호작용하는 화합물
MX2020002553A (es) 2017-09-08 2020-07-22 Hoffmann La Roche Metodos de diagnostico y terapeuticos para el cancer.
EP3752200A1 (en) 2018-02-13 2020-12-23 Vib Vzw Targeting minimal residual disease in cancer with rxr antagonists
SG11202012922VA (en) 2018-07-09 2021-01-28 Boehringer Ingelheim Animal Health Usa Inc Anthelminthic heterocyclic compounds
JP7393808B2 (ja) 2018-11-20 2023-12-07 エヌフレクション セラピューティクス インコーポレイテッド 皮膚障害の処置のためのナフチリジノン－アニリン化合物
CN113498340A (zh) 2018-11-20 2021-10-12 恩福莱克逊治疗有限公司 用于治疗皮肤疾病噻吩基苯胺化合物
WO2020106306A1 (en) 2018-11-20 2020-05-28 Nflection Therapeutics, Inc. Cyanoaryl-aniline compounds for treatment of dermal disorders
US12391705B2 (en) 2018-12-19 2025-08-19 Shy Therapeutics, Llc Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
CA3133100A1 (en) 2019-03-19 2020-09-24 Boehringer Ingelheim Animal Health USA Inc. Anthelmintic aza-benzothiophene and aza-benzofuran compounds
CR20220665A (es) 2020-05-29 2023-07-19 Boehringer Ingelheim Pharma Compuestos heterocíclicos como anthelmínticos
US12371667B2 (en) 2021-05-13 2025-07-29 Washington University Enhanced methods for inducing and maintaining naive human pluripotent stem cells
PE20250675A1 (es) 2021-11-01 2025-03-04 Boehringer Ingelheim Vetmedica Gmbh Compuestos de pirrolopiridazina como antihelminticos
WO2024033381A1 (en) 2022-08-10 2024-02-15 Vib Vzw Inhibition of tcf4/itf2 in the treatment of cancer
WO2026019990A1 (en) 2024-07-18 2026-01-22 Genentech, Inc. Methods of treating cancer with anti-ccr8/anti-cd3 bispecific antibodies

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5328920A (en) 1991-04-17 1994-07-12 Hoechst-Roussel Pharmaceuticals Incorporated Substituted (pyridinylamino)-indoles
WO1993001169A2 (en) 1991-07-05 1993-01-21 Merck Sharp & Dohme Limited Aromatic compounds, pharmaceutical compositions containing them and their use in therapy
US5214204A (en) 1991-07-19 1993-05-25 Abbott Laboratories Arylamidoalkyl-n-hydroxyurea compounds having lipoxygenase inhibitory activity
EP0530537B1 (en) 1991-08-12 1997-01-08 Takeda Chemical Industries, Ltd. Condensed pyrimidine derivatives, their production and use as antitumor agents
EP0545478A1 (en) 1991-12-03 1993-06-09 MERCK SHARP & DOHME LTD. Heterocyclic compounds as tachykinin antagonists
JPH05345780A (ja) 1991-12-24 1993-12-27 Kumiai Chem Ind Co Ltd ピリミジンまたはトリアジン誘導体及び除草剤
US5852046A (en) 1993-08-03 1998-12-22 Hoechst Aktiengesellschaft Benzo-fused heterocyclic compounds having a 5-membered ring processes for their preparation their use as medicaments their use as diagnostic agents and medicaments containing them
US5350748A (en) 1993-08-18 1994-09-27 Warner-Lambert Company 3-thio or amino substituted-benzo[b]thiophene-2-carboxamides and 3-oxygen, thio, or amino substituted-benzofuran-2-carboxamides as inhibitors of cell adhesion
DE4425609A1 (de) 1994-07-20 1996-01-25 Bayer Ag Benzofuranyl- und Benzothienyloxazolidinone
JP4306806B2 (ja) 1997-04-24 2009-08-05 ダウ・アグロサイエンス・エル・エル・シー 有害生物防除性 ３―（置換フェニル）―５―（チエニルまたはフリル）―１，２，４―トリアゾール
GB9723590D0 (en) 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
FR2777886B1 (fr) 1998-04-27 2002-05-31 Adir Nouveaux derives benzothiopheniques, benzofuraniques et indoliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP2002519321A (ja) 1998-06-30 2002-07-02 イーライ・リリー・アンド・カンパニー セロトニン関連系に効果を有するピロリジン、及び、ピロリン誘導体
AR019178A1 (es) 1998-06-30 2001-12-26 Lilly Co Eli Compuestos de 7-(benzo(b)tiofeno, furan e indolpiridil o tetrahidropiridilo), efectivos sobre sistemas relacionados con la serotonina, composicionesfarmaceuticas formuladas con dichos compuestos; compuestos intermediarios utiles para preparar dichos compuestos de tiofeno, furan e indolpiridilo otetr
EP1091741A4 (en) 1998-06-30 2002-12-18 Lilly Co Eli AZEPINE DERIVATIVES PLAYING A ROLE IN SEROTONIN ASSOCIATED SYSTEMS
US6410562B1 (en) 1998-12-18 2002-06-25 Eli Lilly And Company Hypoglycemic imidazoline compounds
HK1041697A1 (zh) * 1999-01-13 2002-07-19 沃尼尔‧朗伯公司 苯并杂环和它们作为mek抑制剂的用途
JP2000204079A (ja) * 1999-01-13 2000-07-25 Warner Lambert Co ジアリ―ルアミン
FR2799756B1 (fr) 1999-10-15 2001-12-14 Adir Nouveaux derives benzothiopheniques, benzofuraniques et indoliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AR027133A1 (es) 1999-12-30 2003-03-12 Lundbeck & Co As H Derivados de heteroarilo, su preparacion y uso.
AU2001273040A1 (en) 2000-06-27 2002-01-08 Du Pont Pharmaceuticals Company Factor xa inhibitors
CN1219753C (zh) * 2000-07-19 2005-09-21 沃尼尔·朗伯公司 4－碘苯氨基苯氧肟酸的氧合酯
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
US6653346B1 (en) 2002-02-07 2003-11-25 Galileo Pharmaceuticals, Inc. Cytoprotective benzofuran derivatives
CA2476624A1 (en) 2002-02-19 2003-08-28 Pharmacia & Upjohn Company Azabicyclic compounds for the treatment of disease
WO2003077914A1 (en) * 2002-03-13 2003-09-25 Array Biopharma, Inc N3 alkylated benzimidazole derivatives as mek inhibitors
EP1482944A4 (en) 2002-03-13 2006-04-19 Array Biopharma Inc NZ ALKYL BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS
US20040009976A1 (en) 2002-04-30 2004-01-15 Kumiko Takeuchi Hypoglycemic imidazoline compounds
GB0214268D0 (en) * 2002-06-20 2002-07-31 Celltech R&D Ltd Chemical compounds
WO2004012671A2 (en) 2002-08-02 2004-02-12 Merck & Co., Inc. Substituted furo [2,3-b] pyridine derivatives
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
CL2003002287A1 (es) * 2002-11-25 2005-01-14 Wyeth Corp COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS
JP2005104838A (ja) 2003-01-09 2005-04-21 Tanabe Seiyaku Co Ltd 縮合フラン化合物
GB0316237D0 (en) 2003-07-11 2003-08-13 Astrazeneca Ab Therapeutic agents
GB0316232D0 (en) 2003-07-11 2003-08-13 Astrazeneca Ab Therapeutic agents
JP4741491B2 (ja) 2003-08-07 2011-08-03 ライジェル ファーマシューティカルズ， インコーポレイテッド 抗増殖剤としての２，４−ピリミジンジアミン化合物および使用
US7144907B2 (en) * 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
DE10351436A1 (de) 2003-11-04 2005-06-09 Merck Patent Gmbh Verwendung von Thienopyrimidinen
WO2005054176A1 (en) 2003-11-25 2005-06-16 Eli Lilly And Company Peroxisome proliferator activated receptor modulators
EA010298B1 (ru) 2003-12-19 2008-08-29 Биовитрум Аб (Пабл) Новые производные бензофурана, используемые для профилактики или лечения нарушений, связанных с 5-ht-рецептором
DE602004010845T2 (de) 2003-12-22 2008-12-04 Basilea Pharmaceutica Ag Aroylfurane und aroylthiophene, die sich für die behandlung von krebs eignen
EP1699488A2 (en) 2003-12-23 2006-09-13 Pfizer Products Incorporated Therapeutic combination for cognition enhancement and psychotic disorders
CA2601983A1 (en) * 2005-04-06 2006-10-12 Astrazeneca Ab Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors
BRPI0615781A2 (pt) * 2005-09-01 2009-06-16 Array Biopharma Inc compostos inibidores de raf e métodos de uso destes
ATE531720T1 (de) 2006-08-21 2011-11-15 Genentech Inc Aza-benzofuranylverbindungen und anwendungsverfahren dafür
CN101553492A (zh) 2006-08-31 2009-10-07 阵列生物制药公司 Raf抑制剂化合物及其使用方法

Also Published As

Publication number Publication date
IL197060A0 (en) 2009-11-18
JP5349306B2 (ja) 2013-11-20
TW200823222A (en) 2008-06-01
KR101475088B1 (ko) 2014-12-23
AU2007286807B2 (en) 2013-03-21
CL2007002431A1 (es) 2008-03-14
ES2528797T3 (es) 2015-02-12
NO20091198L (no) 2009-05-20
EP2069359A1 (en) 2009-06-17
KR20090047538A (ko) 2009-05-12
CA2660963A1 (en) 2008-02-28
EP2069359B1 (en) 2014-11-12
BRPI0714629A2 (pt) 2013-05-07
TWI426078B (zh) 2014-02-11
AR062469A1 (es) 2008-11-12
WO2008024724A1 (en) 2008-02-28
PE20081359A1 (es) 2008-11-27
PE20120049A1 (es) 2012-02-16
IL197060A (en) 2014-12-31
JP2010501584A (ja) 2010-01-21
US20080081821A1 (en) 2008-04-03
AU2007286807A1 (en) 2008-02-28
US7893085B2 (en) 2011-02-22

Similar Documents

Publication Publication Date Title
MX2009001875A (es) Compuestos de aza-benzotiofenilo y metodos de uso de los mismos.
EP2231662B1 (en) 8-anilinoimidazopyridines and their use as anti-cancer and/or anti-inflammatory agents
EP2307364B1 (en) Isoindolone derivatives as mek kinase inhibitors and methods of use
CA2706571C (en) 5-anilinoimidazopyridines and methods of use
US7855216B2 (en) Aza-indolyl compounds and methods of use
EP2220092B1 (en) Azaindolizines and methods of use
MX2010014559A (es) Heterociclos bicíclicos sustituidos y metodos de uso.
MX2009001878A (es) Compuestos de aza-benzofuranilo y metodos de uso.
CN101583616B (zh) 氮杂苯并噻吩基化合物及使用方法
HK1147254B (en) 5-anilinoimidazopyridines and methods of use

Legal Events

Date Code Title Description
FG Grant or registration